Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Azzak34on Apr 01, 2024 4:01pm
114 Views
Post# 35963563

RE:RE:New week, day, month, post, threads

RE:RE:New week, day, month, post, threadsWe're getting there John. We may not get the buyout we're all banking on this year but a good run-up in SP, somewhere in the $5-7 range is highly likely. I think people will have a decision on when to take a decent profit and when to hang on and see if the big payday comes. I have my own number but I'm sure others will vary. 

Google work and research on OVs in general and you'll see the industry is coming around to them and so much work is being done on immune boosting therapies right now. Our "fad" time is coming very soon. 

I also agree that we're in for a hell of a bumpy 2024 in a number of ways, scary for some exciting for others but it's gonna be interesting.  

Keep the faith mate. 
<< Previous
Bullboard Posts
Next >>